QuIBD

Qu Biologics has launched clinical trials for Crohn's disease and ulcerative colitis. Our IBD clinical trials involve QBECO SSI, an investigational new immunotherapy treatment that aims to restore the body's normal immune response in a targeted manner to potentially reverse the chronic inflammation underlying inflammatory bowel disease. The Crohn's disease clinical trial has completed enrollment. If you are interested in participating in a future clinical trial involving Qu Biologics' Site Specific Immumodulators, you can email qucrohnstrial@qubiologics.com indicating your interest. The ulcerative colitis clinical trial is located in Vancouver, BC, Edmonton, AB, and Hamilton, ON. The ulcerative colitis trial is open to Canadian residents. More information about the trials can be found at www.quibd.com.